Ankyra Therapeutics is focused on advancing cancer treatment through its innovative anchored-drug conjugate technology, specifically designed to enhance the retention of therapeutic agents within tumors. Their approach utilizes aluminum hydroxide as an anchor to bind therapeutic molecules, which allows for prolonged anti-tumor immune activation while minimizing systemic side effects associated with drug leakage. This technology aims to improve the therapeutic window, enabling more effective treatment with fewer doses, thereby optimizing patient outcomes and safety.

The company's lead product candidate, ANK-101, is an IL-12 anchored-drug conjugate that has shown promising results in preclinical models, demonstrating potent therapeutic activity with a single dose. By retaining the IL-12 at the tumor site for over 28 days, ANK-101 aims to leverage the cytokine's anti-tumor effects while mitigating the high toxicity typically associated with systemic IL-12 administration. Ankyra's anchored immunotherapy platform not only addresses the challenges of dose-limiting toxicities but also holds the potential to significantly improve the lives of patients with advanced solid tumors.

United States

Ankyra is developing a novel approach for cancer treatment called Anchored Immunotherapy, promoting prolonged immune activation locally while limiting systemic toxicity.

Ankyra Therapeutics

Company Details